PT105058B - Processo para processamento de partículas de ingredientes activos farmacêuticos - Google Patents
Processo para processamento de partículas de ingredientes activos farmacêuticos Download PDFInfo
- Publication number
- PT105058B PT105058B PT105058A PT10505810A PT105058B PT 105058 B PT105058 B PT 105058B PT 105058 A PT105058 A PT 105058A PT 10505810 A PT10505810 A PT 10505810A PT 105058 B PT105058 B PT 105058B
- Authority
- PT
- Portugal
- Prior art keywords
- active ingredient
- pharmaceutical
- pharmaceutically acceptable
- particles
- particle size
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000002245 particle Substances 0.000 title claims abstract description 41
- 239000004480 active ingredient Substances 0.000 title claims description 16
- 238000001035 drying Methods 0.000 claims abstract description 11
- 238000009826 distribution Methods 0.000 claims abstract description 10
- 238000000889 atomisation Methods 0.000 claims abstract description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 238000011946 reduction process Methods 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 241000024192 Aloa Species 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 229960004495 beclometasone Drugs 0.000 claims 1
- FFLJZFAEPPHUCU-UHFFFAOYSA-N benzene;thiophene Chemical class C=1C=CSC=1.C1=CC=CC=C1 FFLJZFAEPPHUCU-UHFFFAOYSA-N 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- -1 formotrex Chemical compound 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 1
- 229960001888 ipratropium Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 abstract description 2
- 238000005549 size reduction Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010951 particle size reduction Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000398147 Aleurodiscus amorphus Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 101100227198 Campylobacter jejuni flaA gene Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- XIRLTVLKWRDXSW-UHFFFAOYSA-N OBO.F Chemical compound OBO.F XIRLTVLKWRDXSW-UHFFFAOYSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 235000021443 coca cola Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000004512 die casting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical compound [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 244000149079 tacso Species 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT105058A PT105058B (pt) | 2010-04-21 | 2010-04-21 | Processo para processamento de partículas de ingredientes activos farmacêuticos |
| EP11718765.8A EP2560620B1 (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
| PCT/GB2011/000631 WO2011131947A2 (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
| PL11718765T PL2560620T3 (pl) | 2010-04-21 | 2011-04-21 | Sposób przetwarzania cząstek aktywnych składników farmaceutycznych |
| SG2012078614A SG185003A1 (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
| US13/642,397 US9956144B2 (en) | 2010-04-21 | 2011-04-21 | Process for particle processing of active pharmaceutical ingredients |
| BR112012026941A BR112012026941A2 (pt) | 2010-04-21 | 2011-04-21 | processos para reduzir o tamanho de um ingrediente farmacêutico ativo, e para fabricar uma composição farmacêutica, ingrediente farmacêutico ativo, composição farmacêutica |
| RU2012149459/15A RU2597790C2 (ru) | 2010-04-21 | 2011-04-21 | Способ обработки частиц активных фармацевтических ингредиентов |
| JP2013505534A JP6347608B2 (ja) | 2010-04-21 | 2011-04-21 | 医薬品有効成分の粒子加工のための方法 |
| MX2012012215A MX338594B (es) | 2010-04-21 | 2011-04-21 | Un procedimiento para el procesamiento de partículas de principios farmaceuticos activos. |
| CN201180024407.2A CN102970978B (zh) | 2010-04-21 | 2011-04-21 | 活性药物成分的颗粒加工方法 |
| CA2796978A CA2796978C (en) | 2010-04-21 | 2011-04-21 | A process for particle processing of active pharmaceutical ingredients |
| IL222596A IL222596B (en) | 2010-04-21 | 2012-10-21 | A process for processing particles of active pharmaceutical ingredients |
| JP2016176303A JP6857467B2 (ja) | 2010-04-21 | 2016-09-09 | 医薬品有効成分の粒子加工のための方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT105058A PT105058B (pt) | 2010-04-21 | 2010-04-21 | Processo para processamento de partículas de ingredientes activos farmacêuticos |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT105058A PT105058A (pt) | 2011-10-21 |
| PT105058B true PT105058B (pt) | 2013-04-17 |
Family
ID=44194836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT105058A PT105058B (pt) | 2010-04-21 | 2010-04-21 | Processo para processamento de partículas de ingredientes activos farmacêuticos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9956144B2 (enExample) |
| EP (1) | EP2560620B1 (enExample) |
| JP (2) | JP6347608B2 (enExample) |
| CN (1) | CN102970978B (enExample) |
| BR (1) | BR112012026941A2 (enExample) |
| CA (1) | CA2796978C (enExample) |
| IL (1) | IL222596B (enExample) |
| MX (1) | MX338594B (enExample) |
| PL (1) | PL2560620T3 (enExample) |
| PT (1) | PT105058B (enExample) |
| RU (1) | RU2597790C2 (enExample) |
| SG (1) | SG185003A1 (enExample) |
| WO (1) | WO2011131947A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691145B2 (en) | 2009-11-16 | 2014-04-08 | Flodesign Sonics, Inc. | Ultrasound and acoustophoresis for water purification |
| US10987361B2 (en) | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| US10993879B2 (en) | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| EP3689364A1 (en) | 2010-02-08 | 2020-08-05 | Shenzhen Evergreen Therapeutics Co., Ltd. | Methods for the use of progestogen as a glucocorticoid sensitizer |
| US9421553B2 (en) | 2010-08-23 | 2016-08-23 | Flodesign Sonics, Inc. | High-volume fast separation of multi-phase components in fluid suspensions |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9272234B2 (en) | 2012-03-15 | 2016-03-01 | Flodesign Sonics, Inc. | Separation of multi-component fluid through ultrasonic acoustophoresis |
| US9783775B2 (en) | 2012-03-15 | 2017-10-10 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US10370635B2 (en) | 2012-03-15 | 2019-08-06 | Flodesign Sonics, Inc. | Acoustic separation of T cells |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9752114B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc | Bioreactor using acoustic standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9796956B2 (en) | 2013-11-06 | 2017-10-24 | Flodesign Sonics, Inc. | Multi-stage acoustophoresis device |
| US9567559B2 (en) | 2012-03-15 | 2017-02-14 | Flodesign Sonics, Inc. | Bioreactor using acoustic standing waves |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9688958B2 (en) | 2012-03-15 | 2017-06-27 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| PT106237B (pt) * | 2012-03-30 | 2015-03-19 | Hovione Farmaci Ncia S A | Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US11324873B2 (en) | 2012-04-20 | 2022-05-10 | Flodesign Sonics, Inc. | Acoustic blood separation processes and devices |
| PT106738B (pt) * | 2013-01-09 | 2015-06-08 | Hovione Farmaciencia Sa | Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico |
| CA2909950A1 (en) * | 2013-04-25 | 2014-10-30 | Flodesign Sonics, Inc. | Excipient removal from pharmacological samples |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| JP6529012B2 (ja) | 2013-10-08 | 2019-06-12 | エイアイ・セラピューティクス・インコーポレーテッド | リンパ脈管筋腫症の処置のためのラパマイシン |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| PT107433B (pt) * | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| MX2016010373A (es) | 2014-02-11 | 2016-11-30 | Lam Therapeutics Inc | Rapamicina para el tratamiento de linfangioleiomiomatosis. |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| PT107567B (pt) * | 2014-03-31 | 2019-02-13 | Hovione Farm S A | Secador por atomização com atomizador múltiplo, método para o aumento de escala de pós para inalação secos por dispositivo de atomização múltiplo e uso de vários atomizadores num secador por atomização |
| NZ724756A (en) | 2014-04-04 | 2023-07-28 | Ai Therapeutics Inc | An inhalable rapamycin formulation for treating age-related conditions |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| AU2015330905B2 (en) * | 2014-10-07 | 2021-02-25 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| US10106770B2 (en) | 2015-03-24 | 2018-10-23 | Flodesign Sonics, Inc. | Methods and apparatus for particle aggregation using acoustic standing waves |
| PT108368B (pt) | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| WO2016176663A1 (en) | 2015-04-29 | 2016-11-03 | Flodesign Sonics, Inc. | Acoustophoretic device for angled wave particle deflection |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US9550134B2 (en) | 2015-05-20 | 2017-01-24 | Flodesign Sonics, Inc. | Acoustic manipulation of particles in standing wave fields |
| US10161926B2 (en) | 2015-06-11 | 2018-12-25 | Flodesign Sonics, Inc. | Acoustic methods for separation of cells and pathogens |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| ES2879238T3 (es) | 2015-07-09 | 2021-11-22 | Flodesign Sonics Inc | Reflectores y cristales piezoeléctricos no planos y no simétricos |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| PT109030B (pt) * | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
| US10710006B2 (en) | 2016-04-25 | 2020-07-14 | Flodesign Sonics, Inc. | Piezoelectric transducer for generation of an acoustic standing wave |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3481361A1 (en) | 2016-05-03 | 2019-05-15 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| SG11202003907WA (en) | 2017-12-14 | 2020-05-28 | Flodesign Sonics Inc | Acoustic transducer drive and controller |
| IL309073A (en) | 2021-06-03 | 2024-02-01 | Arcadia Medicine Inc | Enantiomeric entactogen compounds and methods of their use. |
| US20250387327A1 (en) | 2022-07-04 | 2025-12-25 | Hovione Scientia Limited | Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
| WO2026038127A1 (en) | 2024-08-13 | 2026-02-19 | Lupin Limited | A process for processing micronized active pharmaceutical ingredients |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL165803B1 (pl) | 1990-09-10 | 1995-02-28 | Schering Corp | Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL |
| US6187765B1 (en) * | 1997-10-09 | 2001-02-13 | Schering Corporation | Mometasone furoate suspensions for nebulization |
| US6184765B1 (en) * | 1999-01-07 | 2001-02-06 | Nec Research Institute, Inc. | Switch useful at superconducting temperatures and comprising superconducting material |
| US6555139B2 (en) * | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| GB9925934D0 (en) | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
| GB0125604D0 (en) * | 2001-10-25 | 2001-12-19 | Glaxo Group Ltd | Novel process |
| JP4684545B2 (ja) * | 2002-09-26 | 2011-05-18 | 大日本住友製薬株式会社 | 溶出性の良好なイソキサゾール誘導体経口製剤 |
| WO2005094788A1 (ja) * | 2004-03-31 | 2005-10-13 | Toyama Chemical Co., Ltd. | 難溶性薬物の微粒子分散液およびその製造方法 |
| EP1595534A1 (en) * | 2004-05-13 | 2005-11-16 | Universiteit Utrecht Holding B.V. | Gel composition comprising charged polymers |
| CA2591406A1 (en) * | 2004-12-17 | 2006-06-22 | Cipla Limited | Pharmaceutical compounds and compositions |
| WO2006073154A1 (ja) * | 2005-01-07 | 2006-07-13 | Eisai R&D Management Co., Ltd. | 医薬組成物及びその製造方法 |
| US20060193818A1 (en) * | 2005-02-25 | 2006-08-31 | Southall Michael D | Compositions containing amines and use thereof |
| DE102005011786A1 (de) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| JP4879349B2 (ja) | 2007-07-31 | 2012-02-22 | 大塚製薬株式会社 | アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法 |
| EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| EP2156823A1 (en) * | 2008-08-14 | 2010-02-24 | Pharmatex Italia Srl | Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles |
-
2010
- 2010-04-21 PT PT105058A patent/PT105058B/pt active IP Right Grant
-
2011
- 2011-04-21 RU RU2012149459/15A patent/RU2597790C2/ru active
- 2011-04-21 WO PCT/GB2011/000631 patent/WO2011131947A2/en not_active Ceased
- 2011-04-21 JP JP2013505534A patent/JP6347608B2/ja active Active
- 2011-04-21 CA CA2796978A patent/CA2796978C/en active Active
- 2011-04-21 PL PL11718765T patent/PL2560620T3/pl unknown
- 2011-04-21 MX MX2012012215A patent/MX338594B/es active IP Right Grant
- 2011-04-21 SG SG2012078614A patent/SG185003A1/en unknown
- 2011-04-21 BR BR112012026941A patent/BR112012026941A2/pt not_active Application Discontinuation
- 2011-04-21 US US13/642,397 patent/US9956144B2/en active Active
- 2011-04-21 EP EP11718765.8A patent/EP2560620B1/en active Active
- 2011-04-21 CN CN201180024407.2A patent/CN102970978B/zh active Active
-
2012
- 2012-10-21 IL IL222596A patent/IL222596B/en active IP Right Grant
-
2016
- 2016-09-09 JP JP2016176303A patent/JP6857467B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6857467B2 (ja) | 2021-04-14 |
| US20130203717A1 (en) | 2013-08-08 |
| CA2796978A1 (en) | 2011-10-27 |
| JP2013525338A (ja) | 2013-06-20 |
| MX338594B (es) | 2016-04-25 |
| CN102970978A (zh) | 2013-03-13 |
| US9956144B2 (en) | 2018-05-01 |
| PT105058A (pt) | 2011-10-21 |
| CN102970978B (zh) | 2017-05-10 |
| JP6347608B2 (ja) | 2018-06-27 |
| RU2597790C2 (ru) | 2016-09-20 |
| EP2560620B1 (en) | 2020-09-16 |
| WO2011131947A3 (en) | 2012-01-05 |
| WO2011131947A2 (en) | 2011-10-27 |
| CA2796978C (en) | 2019-07-02 |
| SG185003A1 (en) | 2012-11-29 |
| IL222596B (en) | 2019-03-31 |
| MX2012012215A (es) | 2013-05-09 |
| RU2012149459A (ru) | 2014-05-27 |
| IL222596A0 (en) | 2012-12-31 |
| JP2017019845A (ja) | 2017-01-26 |
| PL2560620T3 (pl) | 2021-04-06 |
| EP2560620A2 (en) | 2013-02-27 |
| BR112012026941A2 (pt) | 2016-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT105058A (pt) | Processo para processamento de partículas de ingredientes activos farmacêuticos | |
| AU2015212618B2 (en) | Assisted particle size reduction process | |
| JP2013510813A (ja) | プロパン−１−スルホン酸｛３−［５−（４−クロロ−フェニル）−１Ｈ−ピロロ［２，３−ｂ］ピリジン−３−カルボニル］−２，４−ジフルオロ−フェニル｝−アミド組成物とその用途 | |
| US20150065547A1 (en) | Esterified cellulose ethers having a specific substituent distribution | |
| ME00243B (me) | Kristalni monohidrat, postupak za njegovo pripremanje i njegova primena za pripremanje lijeka | |
| ME00412B (me) | Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka | |
| CN107567437A (zh) | 5‑氨基‑2,3‑二氢酞嗪‑1,4‑二酮钠盐的晶形、含其的药物制剂及其生产方法 | |
| Rosas et al. | Simultaneous formation of inclusion complex and microparticles containing Albendazole and β-Cyclodextrin by supercritical antisolvent co-precipitation | |
| US20220362167A1 (en) | Water-dispersible cannabidiol product and preparation method therefor | |
| US20010049442A1 (en) | Paroxetine compositions | |
| CN106361724A (zh) | 一种20(R)-人参皂苷Rg3缓释纳米微球组合及其制备方法 | |
| CN105193747B (zh) | 一种含有阿戈美拉汀的冻干口服制剂及其制备方法 | |
| EP3196208B1 (en) | Peptide having osteoclast differentiation and activation inhibition, and use of same | |
| CN103588846B (zh) | 一种丙酸氟替卡松微粒的制备方法及其用途 | |
| PT97541B (pt) | Processo para a preparacao de indoles substituidos | |
| CN102516416A (zh) | 一种肝素酯化物的合成方法 | |
| JP2011518141A (ja) | ステロイドのネブライザー製剤 | |
| CN105250244A (zh) | 一种肺部吸入的姜黄素磷脂复合物壳聚糖微球及其制备方法 | |
| CN115337271A (zh) | 一种匹可硫酸钠颗粒制剂及其制备工艺 | |
| CN115028551A (zh) | 一种叠氮-九甘醇-丙酸的制备方法 | |
| KR102010484B1 (ko) | 20(r)-진세노사이드 rg3 다중아실화 유도체, 이의 제조, 및 용도 | |
| CN114304394A (zh) | 一种包衣肠溶氧化锌及其制备工艺 | |
| CN105315186A (zh) | 一种叶黄素浸膏到高纯度叶黄素酯的纯化工艺 | |
| HK1173448A (en) | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof | |
| CN106883283A (zh) | 环索奈德一水合物及其晶型与制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 20110907 |
|
| FG3A | Patent granted, date of granting |
Effective date: 20130412 |